IGF2BP1 and cancer: m6A modification of PD‐L1 mRNA is recognized by IGF2BP1 which stabilizes the transcript, increasing PD‐L1 expression in bladder cancer cells.[90] METTL14‐induced ICI resistance occurs in cholangiocarcinoma with increased expression of PD‐L1 in cancer cells.